Bearbmagovva

The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study

Furkejuvvon:
Publikašuvnnas:NPJ Breast Cancer vol. 11, no. 1 (2025), p. 96-104
Váldodahkki: Brantley, Kristen D.
Eará dahkkit: Kirkner, Gregory J., Hughes, Melissa E., Varella, Leticia, Suggs, Georgia, Cunningham, Olivia M., Ravikumar, Sanjana, Snow, Craig, Tolaney, Sara M., Sammons, Sarah, Partridge, Ann H., Lin, Nancy U.
Almmustuhtton:
Nature Publishing Group
Fáttát:
Patients
Womens health
Epidermal growth factor
Histology
Metastasis
Age
Kinases
Radiation
Cyclin-dependent kinases
Breast cancer
Liŋkkat:Citation/Abstract
Full Text
Full Text - PDF
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

MARC

LEADER 00000nab a2200000uu 4500
001 3244979863
003 UK-CbPIL
022 |a 2374-4677 
024 7 |a 10.1038/s41523-025-00822-y  |2 doi 
035 |a 3244979863 
045 2 |b d20250101  |b d20251231 
084 |a 274865  |2 nlm 
100 1 |a Brantley, Kristen D.  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Department of Medicine, Harvard School of Medicine, Boston, MA, USA (ROR: https://ror.org/03vek6s52) (GRID: grid.38142.3c) (ISNI: 000000041936754X) 
245 1 |a The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study 
260 |b Nature Publishing Group  |c 2025 
513 |a Journal Article 
520 3 |a The influence of young age at diagnosis on prognosis of patients with metastatic breast cancer (MBC) remains unclear. We examined overall survival (OS) within a single-institution prospective study of patients with de novo or recurrent MBC. Kaplan-Meier curves assessed OS by age (≤35 or ≤40 years as the youngest category) and inferred metastatic tumor subtype. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% CIs for OS by age adjusting for clinical factors. Of 4189 women <75 years, 571 were ≤40 years at MBC diagnosis, of whom 260 were ≤35 years. Over half (52%) died during follow-up (median = 5.3 years, IQR = 2.1–9.8 years). Compared to patients 45–55 years, those ≤35 years at diagnosis experienced worse OS (HR = 1.22, 95%CI 1.00–1.48, p = 0.05). This association was driven by HER2-negative/luminal B-like and hormone receptor-positive/HER2-positive tumors. These findings highlight the need to develop more effective therapies for young patients with this metastatic subtype. 
653 |a Patients 
653 |a Womens health 
653 |a Epidermal growth factor 
653 |a Histology 
653 |a Metastasis 
653 |a Age 
653 |a Kinases 
653 |a Radiation 
653 |a Cyclin-dependent kinases 
653 |a Breast cancer 
700 1 |a Kirkner, Gregory J.  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896) 
700 1 |a Hughes, Melissa E.  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896); Yale Cancer Center, New Haven, CT, USA (ROR: https://ror.org/03j7sze86) (GRID: grid.433818.5) (ISNI: 0000 0004 0455 8431) 
700 1 |a Varella, Leticia  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Department of Medicine, Harvard School of Medicine, Boston, MA, USA (ROR: https://ror.org/03vek6s52) (GRID: grid.38142.3c) (ISNI: 000000041936754X); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896) 
700 1 |a Suggs, Georgia  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910) 
700 1 |a Cunningham, Olivia M.  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896) 
700 1 |a Ravikumar, Sanjana  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896) 
700 1 |a Snow, Craig  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896) 
700 1 |a Tolaney, Sara M.  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Department of Medicine, Harvard School of Medicine, Boston, MA, USA (ROR: https://ror.org/03vek6s52) (GRID: grid.38142.3c) (ISNI: 000000041936754X); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896) 
700 1 |a Sammons, Sarah  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Department of Medicine, Harvard School of Medicine, Boston, MA, USA (ROR: https://ror.org/03vek6s52) (GRID: grid.38142.3c) (ISNI: 000000041936754X); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896) 
700 1 |a Partridge, Ann H.  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Department of Medicine, Harvard School of Medicine, Boston, MA, USA (ROR: https://ror.org/03vek6s52) (GRID: grid.38142.3c) (ISNI: 000000041936754X); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896) 
700 1 |a Lin, Nancy U.  |u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA (ROR: https://ror.org/02jzgtq86) (GRID: grid.65499.37) (ISNI: 0000 0001 2106 9910); Department of Medicine, Harvard School of Medicine, Boston, MA, USA (ROR: https://ror.org/03vek6s52) (GRID: grid.38142.3c) (ISNI: 000000041936754X); Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA (ROR: https://ror.org/05rgrbr06) (GRID: grid.417747.6) (ISNI: 0000 0004 0460 3896) 
773 0 |t NPJ Breast Cancer  |g vol. 11, no. 1 (2025), p. 96-104 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3244979863/abstract/embedded/J7RWLIQ9I3C9JK51?source=fedsrch 
856 4 0 |3 Full Text  |u https://www.proquest.com/docview/3244979863/fulltext/embedded/J7RWLIQ9I3C9JK51?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3244979863/fulltextPDF/embedded/J7RWLIQ9I3C9JK51?source=fedsrch